Literature DB >> 12905530

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.

Malathi Hari1, Hailing Yang, Changqing Zeng, Martin Canizales, Fernando Cabral.   

Abstract

Human brain and testis specific betaIII-tubulin was amplified from a cDNA library, modified to encode a C-terminal hemagglutinin antigen epitope tag, and cloned into a vector that allows tetracycline regulated expression in mammalian cells. Immunofluorescence analysis of transfected Chinese hamster ovary cells demonstrated that expressed HA-tagged betaIII-tubulin is able to assemble with endogenous tubulin into microtubules even though betaIII-tubulin is not a normal constituent of these cells. A stable G418-resistant clone with moderate HAbetaIII-tubulin expression displayed weak (1.5-2-fold) resistance to paclitaxel. A second clone with higher HAbetaIII-tubulin expression could not grow unless tetracycline was present to repress transcription of the transfected cDNA. Analysis of cellular microtubules in each of these clones indicated that incorporation of HAbetaIII-tubulin led to a significant expression-dependent decrease in assembled tubulin. Paclitaxel resistant cells were also directly selected from the transfected cell population using a paclitaxel concentration 4 times higher than the minimum toxic dose. Few cells were able to survive the selection and they grew very slowly. Western blot analysis of these resistant cells revealed very high HAbetaIII-tubulin expression that led to almost complete replacement of endogenous beta-tubulin at steady state. Transfected betaIII-tubulin with no epitope tag behaved in a very similar fashion indicating that presence of the HA tag had no discernible functional effect. The results demonstrate that betaIII-tubulin diminishes microtubule assembly, is toxic when present at high levels, but is able to confer weak resistance to paclitaxel when expressed at moderate levels in mammalian cells. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12905530     DOI: 10.1002/cm.10132

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  52 in total

1.  A ubiquitous beta-tubulin disrupts microtubule assembly and inhibits cell proliferation.

Authors:  Rajat Bhattacharya; Fernando Cabral
Journal:  Mol Biol Cell       Date:  2004-04-30       Impact factor: 4.138

2.  Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer.

Authors:  Dong-Hoe Koo; Hee Jin Lee; Jin-Hee Ahn; Dok Hyun Yoon; Sung-Bae Kim; Gyungyub Gong; Byung Ho Son; Sei Hyun Ahn; Kyung Hae Jung
Journal:  Tumour Biol       Date:  2015-03-01

3.  Molecular basis for class V beta-tubulin effects on microtubule assembly and paclitaxel resistance.

Authors:  Rajat Bhattacharya; Fernando Cabral
Journal:  J Biol Chem       Date:  2009-03-12       Impact factor: 5.157

4.  Docetaxel-carboxymethylcellulose nanoparticles display enhanced anti-tumor activity in murine models of castration-resistant prostate cancer.

Authors:  Bryan Hoang; Mark J Ernsting; Mami Murakami; Elijus Undzys; Shyh-Dar Li
Journal:  Int J Pharm       Date:  2014-05-20       Impact factor: 5.875

5.  Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.

Authors:  Guillaume Ploussard; Stéphane Terry; Pascale Maillé; Yves Allory; Nanor Sirab; Laurence Kheuang; Pascale Soyeux; Nathalie Nicolaiew; Estelle Coppolani; Bernard Paule; Laurent Salomon; Stéphane Culine; Ralph Buttyan; Francis Vacherot; Alexandre de la Taille
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

Review 6.  Microtubules and resistance to tubulin-binding agents.

Authors:  Maria Kavallaris
Journal:  Nat Rev Cancer       Date:  2010-02-11       Impact factor: 60.716

Review 7.  Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.

Authors:  Jonathan D Black; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Womens Health (Lond)       Date:  2014-01

8.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

9.  Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents.

Authors:  C Stengel; S P Newman; M P Leese; B V L Potter; M J Reed; A Purohit
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

10.  The roles of beta-tubulin mutations and isotype expression in acquired drug resistance.

Authors:  J Torin Huzil; Ke Chen; Lukasz Kurgan; Jack A Tuszynski
Journal:  Cancer Inform       Date:  2007-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.